Reviewer's report

Title: Partial Palivizumab Prophylaxis and Increased Risk of Hospitalization Due to Respiratory Syncytial Virus in a Medicaid Population: A Retrospective Cohort Analysis

Version: 2 Date: 27 November 2013

Reviewer: Inge Axelsson

Reviewer's report:

This paper comes from a company with interests in palivizumab. It may be of interest after changes.

Major revisions

p. 2. “a 21% greater risk of hospitalization compared with fully prophylaxed infants (odds ratio 1.21,...”): RR = 1.21 means 21% greater risk but this is not true for OR.

The partially treated cohort had higher pretreatment hospitalization rate and more CLDP and CHD, and probably lower average gestation length. These confounders should be discussed in the Discussion section. I think that the present writing exaggerates the differences in RSV occurrence.


table 2. "Length of Stay (days)”: what do 24.9 and 24.7 mean?

Figures 1, 4. “CHD: congestive heart disease”: do you mean congenital, not congestive?

Level of interest: An article whose findings are important to those with closely related research interests

Quality of written English: Acceptable

Statistical review: No, the manuscript does not need to be seen by a statistician.

Declaration of competing interests:

'I declare that I have no competing interests'